-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 17, 2021, AbbVie announced that the European Commission (EC) has approved the second indication of the interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab), as a single agent or in combination with methamine Pterin (MTX) is used to treat adults with active psoriatic arthritis that are inadequate or intolerant to one or more anti-rheumatic drugs (DMARDs) that alter the progression of the disease
Psoriatic arthritis is a heterogeneous, systemic inflammatory disease with hallmark manifestations in multiple systems (including joints and skin)
Skyrizi selectively blocks IL-23 by binding to the p19 subunit of IL-23
This approval is based on positive data obtained from two randomized, double-blind, multi-center, placebo-controlled Phase 3 clinical trials
▲Skyrizi's performance in the primary and secondary endpoints in two phase 3 clinical trials (picture source: reference [2])
Reference materials:
[1] AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of Skyrizi® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis.
[2] Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients.
(The original text has been deleted)
